Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced the completion of its acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including a biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for total consideration of US $122.5 million. The transaction was executed through Bora's wholly owned subsidiary Bora Biologics USA, LLC. Upon closing, Bora signed a long-term CDMO Service Agreement with MacroGenics.
With the close of the transaction, Bora Biologics now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites: Rockville, Maryland and San Diego, California, and one development facility in Zhubei, Taiwan. This acquisition establishes a US biologics manufacturing platform that sponsors can depend on from development through licensed commercial supply, according to Bobby Sheng, Chairman and CEO of Bora Group.
As regulatory and supply chain dynamics continue to evolve, biotech and pharmaceutical companies are increasingly seeking manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities. With the addition of the Rockville facility, Bora Biologics supports more than 4 active commercial programs, with more than 120 completed GMP batches and supply into multiple global markets including the US, EU, Japan, Canada and the UK.
Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, with clean results at both sites. The combined platform has supported more than 33 biologics and 15 biosimilars, establishing a manufacturing base for biotech and pharmaceutical companies with reduced offshore dependency and domestically anchored infrastructure.
Bora Group intends to integrate its US drug substance capabilities with its existing sterile drug product capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution. For more information, visit Bora Pharmaceuticals and Bora CDMO.
